Top 5 Contagion® News Articles for the Week of September 24, 2017
SEP 30, 2017 | CONTAGION® EDITORIAL STAFF
#5: A Cost-Effective Method to Decrease HCV Infections in High-Risk Communities
Routine, rapid hepatitis C virus (HCV) testing during clinical visits appears to be cost-effective in settings in which there is a high prevalence of HCV and injection drug use, a new study has found.
At present, recommendations from the Centers for Disease Control and Prevention (CDC) advocate for routine, risk-based HCV testing for young adults who inject drugs, and one-time testing for those born between 1945 and 1965. However, given that CDC data suggests that the vast majority of HCV cases in the United States are linked with injection-drug use, it has been hypothesized that more routine testing in these at-risk populations could increase diagnosis and, therefore, proper treatment of the disease.
In a study published on September 9, 2017, in the journal Clinical Infectious Diseases, researchers from the Boston University School of Medicine and School of Public Health, assessed the “clinical benefit and cost-effectiveness” of routine HCV testing for youth in high-risk communities—or those with a high incidence of the disease.
#4: Janssen Submits NDA for Once-Daily, Single-Tablet Regimen to Treat HIV
Today, September 25, 2017, Janssen Research & Development, LLC announced that they have submitted a new drug application (NDA) for a darunavir-based, once-daily, single-tablet regimen for the treatment of HIV in adults and adolescents who are 12 years of age or older.
“If approved, [darunavir 800 mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide/ 10mg] D/C/F/TAF will be the only complete regimen to deliver the potential adherence advantages of a single tablet regimen (STR) with the high genetic barrier to resistance of darunavir and demonstrated safety profile of TAF,” according to the press release.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512